Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Agile?
Agile's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -3.232. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Agile's stock?
Currently, 1 analysts cover Agile's stock, with a consensus target price of $12.00. Analyst ratings provide insights into the stock's expected performance.
What is Agile's revenue over the trailing twelve months?
Over the trailing twelve months, Agile reported a revenue of $21.57M.
What is the EBITDA for Agile?
Agile's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$13.15M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Agile?
Agile has a free cash flow of -$1.71M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Agile have, and what sector and industry does it belong to?
Agile employs approximately 19 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
Financials
- EPS (TTM)
- -3.232
- Revenue (TTM)
- $21.57M
- EBITDA (TTM)
- -$13.15M
- Free Cashflow (TTM)
- -$1.71M
Analyst Ratings
The price target is $12.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
- Employees
- 19
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US00847L3087
- Primary Ticker
- AGRX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet